

CENTER FOR GLOBAL CLINICAL RESEARCH DATA

# Clinical Trial Data Sharing and Reuse A New Reality for Researchers

Ida Sim, MD, PhD, Professor of Medicine, UCSF and Vivli Co-Founder

Rebecca Li, Vivli Executive Director
Faculty Co-Director of Research Ethics, Harvard Center for Bioethics
Harvard Medical School

October 2019

# Agenda

- 1. Why share data?
- 2. What is the role of data standards in data sharing and reuse?
- 3. The Vivli Global Platform for Clinical Data sharing and Reuse as a use case



#### 1. Why Should We Share Our Clinical Research Data

- Funder requirements
- Journal requirements (new as of 2018)
- Publicly stated commitments for industry (BIO, EFPIA, PhRMA)
- Drive new science (integrate data to drive new insights faster)
- Ethical obligations to trial participants
- Enhance and advance your career



# What are Journals Requiring as of July 1, 2018?

The NEW ENGLAND JOURNAL of MEDICINE

#### EDITORIALS



#### Data Sharing Statements for Clinical Trials — A Requirement of the International Committee of Medical Journal Editors

Editors (ICMIE) believes there is an ethical obli-

The International Committee of Medical Journal explained at www.icmje.org/recommendations/ browse/publishing-and-editorial-issues/clinical gation to responsibly share data generated by -trial-registration.html. If the data sharing plan

- Major journals including NEJM, JAMA, The Lancet, BMJ, Annals of Internal Med, PLoS Medicine, and hundreds of others (ICMJE)
- Trial manuscripts must be submitted with a data sharing statement
  - Must describe how you will share your Individual participant-level data (IPD), including who, what, when, where, and why
- IPD sharing is not (yet) required but "editors may take into consideration data sharing statements when making editorial decisions"



# Declaring Your Data Re-use Plans as part of the Trial Registration Record... before the 1<sup>st</sup> patient is enrolled

- Data sharing plan is part of the ClinicalTrials.gov registration record
- As of <u>1 January 2019</u>, ICMJE requires registration of your data sharing plan at time of trial registration.

#### **▼ 12. IPD Sharing Statement**


#### Plan to Share IPD

Definition: Indicate whether there is a plan to make individual participant data (IPD) collected in this study, including data dictionaries, available to other researchers (typically after the end of the study). Select one.

- Yes: There is a plan to make IPD and related data dictionaries available.
- No: There is not a plan to make IPD available.
- Undecided: It is not yet known if there will be a plan to make IPD available.



# Many Patients Expect Data Sharing and Reuse



NEJM Aligning Incentives for Sharing Clinical Trial Data Summit, Boston, MA. April 2017



# "Patients don't have patience"

Why is data used only one time to answer one question (the primary endpoint) rather than leveraging participants' contributions to answer multiple questions to understand disease and find treatments?



### Barriers to Data Sharing (IPD) for Academics

- For most academic trialists (Data Contributors)
  - secure data hosting and sharing platforms not available or limited to within the institution
  - no standard data use agreements
  - no independent review process available to adjudicate data requests
  - cost and difficulty of de-identifying IPD and making it available
  - All this makes it difficult to meet data sharing requirements
- For Data Users
  - difficult to discover what IPD is available for sharing
  - combining datasets from different platforms is resource- and timeintensive
  - different data standards, data requirements, security standards, policies



# The Role of Data Standards in Data Sharing and Reuse


- Increasing the number of datasets that use data standards will allow meta-analysts to more easily harmonize and integrate studies and perform analyses such as:
  - Conducting new subgroup analyses
  - Model prognostic or diagnostic data
  - Aggregate studies with time to event outcomes such as survival



# What Data is Shared Through Vivli?

Item	Description
Recommended Set	
Study protocol	Final protocol with all amendments
Data dictionary	Detailed descriptions of each variable in the dataset, including the definition, source, coding, etc. of the variable
Statistical Analysis Plan	Description of the principal features of the analyses described in the protocol
Clinical Study Report (CSR)	Report that summarizes the efficacy and safety data from the study (after regulatory decision)
IPD dataset	Final cleaned individual participant-level data, de-identified/anonymized
Optional	
Analytic code	Software code used to carry out prespecified and additional analyses
Analysis ready IPD dataset	Dataset in a format used to carry out a sponsor's analyses
Case report forms	Forms used to collect the data that is described in the protocol for each trial participant
NOTE: *this is a subset of the entire full data package and includes the data that underlies the publication findings (tables, figures)	

### Data Sharing May Drive Adoption of CDEs



Li, Rebecca, and Ida Sim. "How Clinical Trial Data Sharing Platforms Can Advance the Study of Biomarkers." *The Journal of Law, Medicine & Ethics* 47, no. 3 (2019): 369-373.



# Agenda

- 1. Why share data?
- 2. What is the role of data standards in data sharing and reuse?
- 3. The Vivli Global Platform for Clinical Data sharing and Reuse as a use case



# Introducing Vivli

#### THE ENTITY

- Non-profit organization
- Convening function
  - Biomedical industry (pharma, bio, device)
  - Academia
  - Non-profit funders and foundations
  - Government (funders and regulators)
  - Patient/patient advocates
- Governance and policy
  - Harmonizing language & agreements
  - Move culture of data sharing
- Advocacy
  - Lowering barriers
  - Promoting incentives
- Oversight of implementation

#### THE PLATFORM

- A user-friendly, secure, state-of-the art data sharing and computing platform
- Serving the international community, including trials from any disease, country, sponsor, funder, or investigator
  - Open search
  - Robust security
  - Modern tools and technologies

## Vivli Solution Models for Data Sharing

#### **Institutional Sharing**

- Institutional membership
- Ensures all researchers at an institution or division have access to a central sharing resource
- DOI minted for credit and citation

# Individual Researcher/ Team Sharing and Reuse

- Covers single publication or trial
- Recognizes life cycle of grant is not the same as life cycle of sharing
- DOI minted for credit and citation



# Vivli Diverse Membership











































# Summary: Benefits of Sharing through Vivli

- **Ease of sharing** Sharing de-identified data is facilitated through either institutional memberships in Vivli or individually per dataset
- Citation DOIs allow for citation and credit of your research data
- Metrics Yearly metrics on number of data requests, resulting publications, etc.
- Long-term archiving Archive your trials on Vivli (at least 25 years)
- Post-grant data sharing Management of IPD sharing that continues even after grant funds end
- Funder and journal mandates Easily fulfill requirements for data sharing plans





CENTER FOR GLOBAL CLINICAL RESEARCH DATA

#### How to Access Data in Vivli?



2M
Participants from
109
countries



# Secure Environment Bridges Multiple Platforms




# Johnson Johnson







#### Vivli Secure Environment



- STATA
- MS Office
- R
- Jupyter Notebook
- Python
- SAS



# Vivli is a Global Data Platform – Agnostic to Disease, Funder or Data Contributor

Irritable Bowel Syndrome Bacterial Peritonitis Glaucoma Endometriosis Kidney cancer Non Hodgkins Lymphoma Epilepsy HIV Breast cancer Cystic Fibrosis Diabetes Mellitus Insomnia Coronary Artery Bypass Surgery Schizophrenia Bariatric Obesity Atrial Fibrillation Fibromyalgia Cancer Traumatic Brain injury Trauma
Huntington's Disease Dabigatran Atorvastatin Crohn's Diabetes Hepatitis CHepatitis Autism Hidradenitis Disease Hypertension Myocardial Arthritis Interleukin-6 Zoloft Psoriasis Statin Endometriosis Depression Heart-Failure Bipolar disorder Cannabinoids Asthma Lung cancer Lymphoma Multiple Sclerosis Sickle Cell disease Atopic Dermatitis Tumor burden Vitamin D Total Joint Replacement Cancer Vedolizumab Pulmonary Arterial Hypertension Infarction Hemophilia Sleep Apnea Edoxaban Type 1 Diabetes Mellitus HPV Humira Colorectal Cancer Osteoarthritis Lymphoma Stroke Ulcerative Colitis Vitiligo



#### Data Request and Access Process

#### SEARCH

#### Search Vivli platform

for information about available studies.

#### **REQUEST**

#### Request

IPD data package.

Each Data Request

reviewed
according to
contributor's
publicly stated
requirements.



#### **ACCESS**

Access data from approved requests in Vivli's secure research environment or downloaded with permission.



#### **ANALYZE**

Use robust

analytical tools
to combine and
analyze multiple
data sets



Completed research results assigned a DOI.

Researchers may use the Vivli platform to meet their **publication** requirements.







Log on to

# Vivli.org

- Explore the "thousands of trials available via the Vivli platform
- Begin your search
- Contact <u>support@vivli.org</u> with questions

